Last update 01 Nov 2024

Superficial gastritis

Last update 01 Nov 2024

Basic Info

Synonyms

Superficial gastritis, Superficial gastritis (disorder), gastritis superficial

+ [4]

Introduction-

Drugs associated with Superficial gastritis

Shenlian Hewei Capsule

Target-

Mechanism-

Active Org.

Nanjing Shenqu Pharmaceutical Technology Service Co., Ltd.

Originator Org.

Nanjing Shenqu Pharmaceutical Technology Service Co., Ltd.

Active Indication

Gastritis, Atrophic [+1]

Inactive Indication-

Drug Highest PhasePhase 3

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Xiasa Dexi Capsule

Target-

Mechanism-

Active Org.

Tibetan Hospital of Ruoergai County, Sichuan Province [+2]

Originator Org.-

Active Indication

Chronic superficial gastritis [+1]

Inactive Indication-

Drug Highest PhasePhase 2

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with Superficial gastritis

ChiCTR2200062828 / SuspendedEarly Phase 1IIT

Based on resting state fMRI to explore the therapeutic effect of acupressure stimulation of ST-36-Zusanli in improving the symptoms of chronic superficial gastritis and the central-humoral-metabolic mechanism

Start Date12 Aug 2022

Sponsor / Collaborator-

CTR20140047 / RecruitingPhase 2

夏萨德西胶囊治疗慢性浅表性胃炎（胃热食滞证）随机、双盲、安慰剂平行对照、多中心Ⅱa期临床试验

[Translation] A randomized, double-blind, placebo-controlled, multicenter phase IIa clinical trial of Xiasadexi capsules in the treatment of chronic superficial gastritis (stomach heat and food stagnation syndrome)

评价夏萨德西胶囊治疗慢性浅表性胃炎胃热食滞证的安全性和有效性，同时进行剂量探索，为下一步临床试验提供依据

[Translation]

To evaluate the safety and efficacy of Xiasadexi Capsules in the treatment of chronic superficial gastritis with stomach heat and food stagnation, and to explore the dose to provide a basis for the next clinical trial

Start Date24 Oct 2013

Sponsor / Collaborator

Sichuan Academy of Chinese Medicine Sciences

[+2]

CTR20131838 / CompletedPhase 2

参连和胃胶囊治疗非萎缩性胃炎(寒热错杂证)临床安全性与有效性随机、双盲、安慰剂平行对照、多中心临床研究

[Translation] A randomized, double-blind, placebo-controlled, multicenter clinical study on the safety and efficacy of Shenlianhewei Capsule in the treatment of non-atrophic gastritis (cold-heat syndrome).

初步评价参连和胃胶囊治疗非萎缩性胃炎(寒热错杂证)的临床有性效和安全性

[Translation]

Preliminary evaluation of the clinical efficacy and safety of Shenlianhewei capsule in the treatment of non-atrophic gastritis (cold-heat syndrome)

Start Date23 May 2011

Sponsor / Collaborator

Nanjing Shenqu Pharmaceutical Technology Service Co., Ltd.

100 Clinical Results associated with Superficial gastritis

100 Translational Medicine associated with Superficial gastritis

0 Patents (Medical) associated with Superficial gastritis

495

Literatures (Medical) associated with Superficial gastritis

10 Sep 2024·Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi

[Exploratory study of starting age and interval of gastroscopy for different gastric mucosal lesions].

Article

Author: Jin, M J ; Shui, L M ; Li, J Y ; Sun, Y X ; Lin, H B ; Shen, P ; Wang, J B ; Jiang, Z Q ; Zhu, Z H ; Tang, M L ; Chen, K

Objective: To understand the current status of gastroscopy in diagnosing gastric lesions in general population, and to recommend the optimal age for the first gastroscopy and intervals for repeated gastroscopy. Methods: The gastroscopy records of residents aged 18-80 years in Yinzhou District of Ningbo, Zhejiang Province, between April 2010 and December 2021 were analyzed retrospectively. The detections of gastric lesions across different years, age and genders were described. Goodness of fit tests were applied to compare the differences in detection rates of different lesions in first-time endoscopy in different age groups and different populations. Generalized additive models were used to fit the trend of age specific gastric lesion detection rate explore the optimal age for gastroscopy. The appropriate gastroscopy intervals were determined according to the progress of the gastric lesions detected in repeated gastroscopy. Results: A total of 237 751 participants with 344 398 gastroscopy records were included in analyses. A total of 5 597 cases of chronic atrophic gastritis (CAG), 9 796 cases of intestinal metaplasia (IM), 165 cases of low-grade intraepithelial neoplasia (LGIN), 52 cases of high-grade intraepithelial neoplasia (HGIN) and 435 cases of gastric cancer were detected by the first gastroscopy. The overall detection rate of gastric lesions increased significantly in age group 45-70 years, and remained stable after 70 years old, with LGIN and HGIN showing notable increases at 50 and 55 years old, respectively. Repeated gastroscopy detected CAG, IM, LGIN, and HGIN at a higher rate compared with the first gastroscopy. Normal/superficial gastritis progressed in 3-5 years, whereas CAG or more severe lesions progressed in 1-6 years. Conclusion: Gastroscopy is recommended for general population aged 45 years and above. Furthermore, gastroscopy can be performed every 3-5 years for individuals with normal endoscopy results and once a year for patients with CAG or more severe gastric lesions.

01 Jun 2024·Zhongguo shi yan xue ye xue za zhi

[Clinical Observation on Haploid Hematopoietic Stem Cells Combined with Umbilical Cord Blood Double Transplantation for Aplastic Anaemia in Children].

Article

Author: Zhang, Wen-Bang ; Chen, Xing-Hua ; Liu, Huan-Jun ; Guo, Shu-Xia

OBJECTIVETo explore the efficacy and safety of haploidentical hematopoietic stem cell transplantation combined with umbilical cord blood infusion for the treatment of aplastic anaemia in children.METHODSNine cases of children with aplastic anaemia treated with umbilical cord blood combined with haploidentical hematopoietic stem cell transplantation at the People's Hospital of Henan University of Chinese Medicine from January 1, 2021 to September 15, 2023 with a median age of 11(2-13) years and a median follow up of 18(7.5-21) months were included, and the clinical data were retrospectively analyzed. Hematopoiesis reconstitution, the incidence of graft-versus-host disease(GVHD), infections and survival of the patients were analyzed.RESULTSAll 9 children were successfully implanted. The median time to neutrophil and platelet implantation was 11.11±1.27 d and 12.44±3.36 d, respectively. One case developed acute gastrointestinal GVHD of degree I, which was improved after treatment, and the patient developed superficial gastritis and chronic gastrointestinal GVHD at a later stage, which is currently under clinical follow-up. Acute GVHD of II-IV degree was 0%. Hemorrhagic cystitis in 3 cases, CMV infection in 5 cases and bacterial and fungal infections in 5 cases improved with symptomatic treatment.All 9 children demonstrated complete donor chimerism within 1 month after transplantation, at two years of follow-up, all nine children survived without recurrence or development of grade II-IV GVHD, and there were no children with transplant-related deaths.CONCLUSIONHaploidentical hematopoietic stem cell transplantation combined with umbilical cord blood transfusion for aplastic anaemia in children has a low incidence and mild degree of GVHD, with significant efficacy, and can be used as a therapeutic option for children without an HLA full donor chimeric match.

01 Jan 2024·The American Journal of Pathology

Alternative Splicing Factor Heterogeneous Nuclear Ribonucleoprotein U as a Promising Biomarker for Gastric Cancer Risk and Prognosis with Tumor-Promoting Properties

Article

Author: Sun, Li-Ping ; Li, Hao ; Wu, Yi-Jun ; Yuan, Yuan ; Jing, Jing-Jing ; Wang, Meng-Ya ; Dong, Ying-Ying

Gastric cancer (GC) is a major global health concern with poor outcomes. Heterogeneous nuclear ribonucleoprotein U (HNRNPU) is a multifunctional protein that participates in pre-mRNA packaging, alternative splicing regulation, and chromatin remodeling. Its potential role in GC remains unclear. In this study, the expression characteristics of HNRNPU were analyzed by The Cancer Genome Atlas data, Gene Expression Omnibus data, and then further identified by real-time quantitative PCR and immunohistochemistry using tissue specimens. From superficial gastritis, atrophic gastritis, and hyperplasia to GC, the in situ expression of HNRNPU protein gradually increased, and the areas under the curve for diagnosis of GC and its precancerous lesions were 0.911 and 0.847, respectively. A nomogram integrating HNRNPU expression, lymph node metastasis, and other prognostic indicators exhibited an area under the curve of 0.785 for predicting survival risk. Knockdown of HNRNPU significantly inhibited GC cell proliferation, migration, and invasion and promoted apoptosis in vitro. In addition, RNA-sequencing analysis showed that HNRNPU could affect alternative splicing events in GC cells, with functional enrichment analysis revealing that HNRNPU may exert malignant biological function in GC progression through alternative splicing regulation. In summary, the increased expression of HNRNPU was significantly associated with the development of GC, with a good performance in diagnosing and predicting the prognostic risk of GC. Functionally, HNRNPU may play an oncogenic role in GC by regulating alternative splicing.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Superficial gastritis

Basic Info

Related

Analysis